Syncona launches new gene therapy company Beacon Therapeutics

We are excited to launch a new leading ophthalmic gene therapy company Beacon Therapeutics in a £96 million Series A financing. Beacon has been created by combining Applied Genetic Technologies Corporation's (AGTC’s) late-stage X-linked retinitis pigmentosa (XLRP) programme with two proprietary pre-clinical programmes, including one from the University of Oxford.